Nuclear Science and Techniques

《核技术》(英文版) ISSN 1001-8042 CN 31-1559/TL     2019 Impact factor 1.556

Nuclear Science and Techniques ›› 2009, Vol. 20 ›› Issue (5): 302-306 doi: 10.13538/j.1001-8042/nst.20.302-306

• RADIOCHEMISTRY, RADIOPHARMACEUTICALS AND NUCLEAR MEDICIN • Previous Articles     Next Articles

Preparation and biodistribution of 99Tcm-PIDP as bone imaging agent

CHEN Chuanqing1,2 LUO Shineng1,2,* LIN Jianguo1 YANG Min1 YE Wanzhong1 QIU Ling1 SANG Guangming2 XIA Yongmei2   

  1. 1Key Laboratory of Nuclear Medicine, Ministry of Health, Jiangsu Key Laboratory of Molecular Nuclear Medicine, Jiangsu Institute of Nuclear Medicine, Wuxi 214063, China 2School of Chemical and Materials Engineering, Jiangnan University, Wuxi 214122, China
PDF ShareIt Export Citation
CHEN Chuanqing, LUO Shineng, LIN Jianguo, YANG Min. Preparation and biodistribution of 99Tcm-PIDP as bone imaging agent.Nuclear Science and Techniques, 2009, 20(5): 302-306     doi: 10.13538/j.1001-8042/nst.20.302-306

Abstract:

A novel zoledronic acid derivative, 1-hydroxy-2-(2-propyl-1H-imidazol-1-yl)ethane-1,1-diyldiphosphonic acid (PIDP), was synthesized by three-step reactions from 2-propyl-1H-imidazole. It was labeled with 99Tcm in conditions of 0.1 mg SnCl2·2H2O at pH 6.0 and 99TcmO4 ? in aqueous solution for 20 min at room temperature. The labeling yield and radiochemical purity of 99Tcm-PIDP are both higher than 95%. The biodistribution results show that the bone uptake is up to 8.47%ID/g which is the maximum of bone uptake at 30 min after injection of 99Tcm-PIDP in mice. The pharmacokinetic parameters can be estimated from the exponential equation of C=59.565e-11.307t + 2.069e-1.211t. The clear bone image of rabbit was obtained at 120 min after injection of 99Tcm-PIDP. The results indicate that 99Tcm-PIDP has highly selective uptake in the skeletal and low uptake, rapid clearance in soft tissues, so it would be a potential novel bone imaging agent.

Key words: Diphosphonic acid, Bone imaging agent, 99Tcm-PIDP, Biodistribution